Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients

AZD7442 (tixagevimab-cilgavimab) is a combination of two human monoclonal antibodies for pre-exposure prophylaxis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients who do not mount a reliable vaccine response. Foremost among these are hematologic mali...

Descripción completa

Detalles Bibliográficos
Autores principales: Laracy, Justin C., Yan, Judy, Steiger, Samantha N., Tan, Carrie A., Cohen, Nina, Robilotti, Elizabeth V., Fender, Jerome, Cohen, Sara, Korde, Neha, Lee-Teh, Melissa, Noy, Ariela, Oved, Joseph H., Roeker, Lindsey E., Shah, Gunjan, Babady, N. Esther, Kamboj, Mini, Seo, Susan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Articlec - Non-Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620572/
https://www.ncbi.nlm.nih.gov/pubmed/37345467
http://dx.doi.org/10.3324/haematol.2023.283015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620572/
https://www.ncbi.nlm.nih.gov/pubmed/37345467
http://dx.doi.org/10.3324/haematol.2023.283015

Ejemplares similares